MX384751B - Tratamiento del cáncer con una combinación de plinabulina y taxano. - Google Patents
Tratamiento del cáncer con una combinación de plinabulina y taxano.Info
- Publication number
- MX384751B MX384751B MX2016004441A MX2016004441A MX384751B MX 384751 B MX384751 B MX 384751B MX 2016004441 A MX2016004441 A MX 2016004441A MX 2016004441 A MX2016004441 A MX 2016004441A MX 384751 B MX384751 B MX 384751B
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- taxane compound
- taxane
- plinabulin
- cancer treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 229940123237 Taxane Drugs 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 4
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title 1
- -1 taxane compound Chemical class 0.000 abstract 4
- UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 abstract 3
- 229950011498 plinabulin Drugs 0.000 abstract 3
- 230000003247 decreasing effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 108010054981 dehydrophenylahistin Proteins 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000004235 neutropenia Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta invención proporciona un método de tratamiento del cáncer novedoso en el cual la plinabulina (t-butil-deshidrofenilhistina o NPI-2358) y un compuesto de taxano (como el docetaxel) son usados en combinación. Nuestro estudio ha mostrado que la combinación óptima de inyección de plinabulina después del compuesto de taxano tiene eficacia mejorada inesperada en poblaciones de tumores grandes en modelos con animales y en pacientes con cáncer NSCLC en comparación con el tratamiento con compuesto de taxano solo. Además, esta combinación óptima puede alcanzar un efecto inesperadamente seguro en la disminución de los efectos laterales insoportables, incluyendo la disminución en sus tasas neutropenias en todos los grados y disminución del uso de G-CFS en pacientes con cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2013/085075 WO2015051543A1 (en) | 2013-10-11 | 2013-10-11 | Cancer treatment with combination of plinabulin and taxane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016004441A MX2016004441A (es) | 2016-10-28 |
| MX384751B true MX384751B (es) | 2025-03-14 |
Family
ID=52812462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004441A MX384751B (es) | 2013-10-11 | 2013-10-11 | Tratamiento del cáncer con una combinación de plinabulina y taxano. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10596169B2 (es) |
| EP (1) | EP3076972B1 (es) |
| JP (1) | JP6411523B2 (es) |
| KR (1) | KR102225371B1 (es) |
| CN (1) | CN105705148B (es) |
| AU (1) | AU2013402794B2 (es) |
| BR (1) | BR112016007946A2 (es) |
| CA (1) | CA2926771C (es) |
| DK (1) | DK3076972T3 (es) |
| ES (1) | ES2902665T3 (es) |
| IL (1) | IL244984B (es) |
| MX (1) | MX384751B (es) |
| MY (1) | MY185650A (es) |
| NZ (1) | NZ719049A (es) |
| RU (1) | RU2662298C2 (es) |
| SG (1) | SG11201602637QA (es) |
| WO (1) | WO2015051543A1 (es) |
| ZA (1) | ZA201602380B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7243021B2 (ja) * | 2015-02-12 | 2023-03-22 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
| US10076518B2 (en) | 2015-03-06 | 2018-09-18 | Beyondspring Pharmaceuticals, Inc. | Method of treating a brain tumor |
| US10238650B2 (en) | 2015-03-06 | 2019-03-26 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a RAS mutation |
| JP6969848B2 (ja) | 2015-07-13 | 2021-11-24 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | プリナブリン組成物 |
| JP2019511565A (ja) | 2016-02-08 | 2019-04-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | ツカレゾールまたはそのアナログを含む組成物 |
| EP3463337A4 (en) * | 2016-06-06 | 2020-02-12 | Beyondspring Pharmaceuticals, Inc. | COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| CN110381938A (zh) * | 2017-02-01 | 2019-10-25 | 大连万春布林医药有限公司 | 减少中性粒细胞缺乏症的方法 |
| BR112019018880A2 (pt) * | 2017-03-13 | 2020-04-14 | Beyondspring Pharmaceuticals Inc | composições de plinabulina e seu uso |
| CN109498627B (zh) * | 2017-09-15 | 2021-06-04 | 深圳华大海洋科技有限公司 | 一种治疗肿瘤的药物组合物及其应用 |
| BR112020014960A2 (pt) | 2018-01-24 | 2020-12-22 | Beyondspring Pharmaceuticals, Inc. | Composição e método para redução de trombocitopenia |
| BR112020015758A2 (pt) * | 2018-02-01 | 2020-12-08 | Beyondspring Pharmaceuticals, Inc. | Composição e método para reduzir neutropenia induzida por quimioterapia através da administração de plinabulina e agente de g-csf |
| CN108524442B (zh) * | 2018-06-05 | 2022-01-28 | 深圳海王医药科技研究院有限公司 | 一种抗肿瘤药物的注射剂及其制备方法 |
| JP2018199726A (ja) * | 2018-09-26 | 2018-12-20 | ビヨンドスプリング インコーポレイテッド | プリナブリン及びタキサンの組合せがん治療 |
| CN113661253B (zh) * | 2018-11-14 | 2024-03-12 | 大连万春布林医药有限公司 | 微管蛋白结合剂治疗癌症的方法 |
| CN110507653B (zh) * | 2019-08-02 | 2022-12-02 | 北京赛而生物药业有限公司 | 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用 |
| CN113613654B (zh) * | 2019-10-15 | 2024-01-26 | 大连万春布林医药有限公司 | 普那布林在制备增加非转移性乳腺癌患者触珠蛋白的药物中的用途 |
| CA3215047A1 (en) * | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| CN117860672A (zh) | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| PT1529044E (pt) | 2002-08-02 | 2008-01-14 | Nereus Pharmaceuticals Inc | Desidrofenila-histinas e os seus análogos e a síntese de desidrofenila-histinas e os seus análogos |
| BRPI0506655A (pt) * | 2004-02-04 | 2007-05-08 | Nereus Pharmaceuticals Inc | dehidrofenilahistinas e seus análogos, e sìntese de dehidrofenilahistinas e seus análogos |
| GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| CA2905418C (en) | 2013-03-13 | 2023-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
-
2013
- 2013-10-11 JP JP2016547208A patent/JP6411523B2/ja active Active
- 2013-10-11 WO PCT/CN2013/085075 patent/WO2015051543A1/en not_active Ceased
- 2013-10-11 BR BR112016007946A patent/BR112016007946A2/pt not_active Application Discontinuation
- 2013-10-11 NZ NZ719049A patent/NZ719049A/en unknown
- 2013-10-11 DK DK13895342.7T patent/DK3076972T3/da active
- 2013-10-11 EP EP13895342.7A patent/EP3076972B1/en active Active
- 2013-10-11 KR KR1020167012255A patent/KR102225371B1/ko active Active
- 2013-10-11 AU AU2013402794A patent/AU2013402794B2/en active Active
- 2013-10-11 SG SG11201602637QA patent/SG11201602637QA/en unknown
- 2013-10-11 RU RU2016112608A patent/RU2662298C2/ru active
- 2013-10-11 ES ES13895342T patent/ES2902665T3/es active Active
- 2013-10-11 CA CA2926771A patent/CA2926771C/en active Active
- 2013-10-11 MY MYPI2016000620A patent/MY185650A/en unknown
- 2013-10-11 US US15/028,376 patent/US10596169B2/en active Active
- 2013-10-11 MX MX2016004441A patent/MX384751B/es unknown
- 2013-10-11 CN CN201380080185.5A patent/CN105705148B/zh active Active
-
2016
- 2016-04-07 IL IL244984A patent/IL244984B/en unknown
- 2016-04-08 ZA ZA2016/02380A patent/ZA201602380B/en unknown
-
2020
- 2020-03-17 US US16/821,348 patent/US20200281921A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2662298C2 (ru) | 2018-07-25 |
| CN105705148A (zh) | 2016-06-22 |
| IL244984B (en) | 2022-05-01 |
| US20200281921A1 (en) | 2020-09-10 |
| AU2013402794A1 (en) | 2016-05-12 |
| EP3076972B1 (en) | 2021-10-06 |
| US10596169B2 (en) | 2020-03-24 |
| CA2926771A1 (en) | 2015-04-16 |
| JP6411523B2 (ja) | 2018-10-24 |
| MX2016004441A (es) | 2016-10-28 |
| ES2902665T3 (es) | 2022-03-29 |
| CA2926771C (en) | 2022-07-05 |
| EP3076972A4 (en) | 2017-12-20 |
| AU2013402794B2 (en) | 2020-02-27 |
| NZ719049A (en) | 2020-06-26 |
| BR112016007946A2 (pt) | 2017-09-12 |
| RU2016112608A (ru) | 2017-11-16 |
| WO2015051543A8 (en) | 2016-04-21 |
| SG11201602637QA (en) | 2016-05-30 |
| US20160250209A1 (en) | 2016-09-01 |
| CN105705148B (zh) | 2021-03-23 |
| IL244984A0 (en) | 2016-05-31 |
| JP2016536352A (ja) | 2016-11-24 |
| EP3076972A1 (en) | 2016-10-12 |
| MY185650A (en) | 2021-05-27 |
| KR20160078987A (ko) | 2016-07-05 |
| KR102225371B1 (ko) | 2021-03-10 |
| WO2015051543A1 (en) | 2015-04-16 |
| DK3076972T3 (da) | 2022-01-03 |
| ZA201602380B (en) | 2022-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX384751B (es) | Tratamiento del cáncer con una combinación de plinabulina y taxano. | |
| PH12019501197A1 (en) | Therapeutically active compounds and their methods of use | |
| MA40437A (fr) | Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux | |
| MX2015011783A (es) | Metodos para tratar tumores solidos pediatricos. | |
| MX377729B (es) | Métodos para tratamiento del melanoma. | |
| MX2017007321A (es) | Terapias de combinacion. | |
| PH12017550063A1 (en) | Combination therapies for treating cancers | |
| PH12016500164B1 (en) | Therapeutically active compounds and their methods of use | |
| WO2013177187A3 (en) | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents | |
| EA201491330A1 (ru) | Терапевтически активные соединения и способы их использования | |
| MX370567B (es) | Tratamiento de mielosupresion. | |
| MX2015014773A (es) | Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja. | |
| MX2016000131A (es) | Nanoparticulas polimericas de docetaxel para el tratamiento de cancer. | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| CA2908742C (en) | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer | |
| ZA201708686B (en) | Nanoparticles for use as a therapeutic vaccine | |
| MX380835B (es) | Terapia de combinación pac-1. | |
| EA201690445A1 (ru) | Лечение рака | |
| PH12016501101A1 (en) | Veliparib in combination with carboplatin for the treatment of triple negative breast cancer | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
| MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. | |
| MX2021001081A (es) | Terapia de combinacion para el tratamiento del cancer. | |
| HK1229712A1 (en) | Cancer treatment with combination of plinabulin and taxane |